International consortium to provide recommendations for understanding PRO data in cancer clinical trials An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials. SISAQOL-IMI (Setting International Standards of Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials - IMI) will establish guidance on how to...